Expert Interview
Discussing the data from the Phase 2b TRANSFORM tria of Calliditas' setanaxib, a NOX enzyme inhibitor in treating primary biliary cholangitis
Ticker(s): CALTInstitution: Piedmont Transplant Institute
- Transplant hepatologist and the Medical Director of Piedmont’s Hepatology and Liver Transplant Program; Clinical Assistant Professor of Medicine at Mercer University School of Medicine
- Treats 45 patients per year with PBC
- Interests include viral hepatitis, alcohol related liver disease, acute on chronic liver failure, metabolic associated steatotic liver disease (MASH/MAFLD), autoimmune liver diseases, autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
